Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

CAP TODAY

Put It on the Board

March 2022—The CAP was one of eight pathology and laboratory organizations to endorse in a joint statement the use of the CKD-EPI 2021 race-free equations for calculating estimated glomerular filtration rate. The others are the Academy of Clinical Laboratory Physicians and Scientists, American Association of Clinical Chemistry, American Society for Clinical Pathology, Association of Pathology Chairs, Clinical Laboratory Management Association, National Independent Laboratory Association, and Society of American Federated Medical Laboratory Scientists (the views of the SAFMLS do not represent the views of the U.S. government). Following is the statement they released on Jan. 31.

BD Kiestra IdentifA receives 510(k) clearance

February 2022—BD announced it has received 510(k) clearance from the FDA for the BD Kiestra IdentifA system, which is designed to automate the preparation of microbiology bacterial identification testing. The company says that by automating what are typically cumbersome manual steps, the BD Kiestra IdentifA may reduce the potential for human error when preparing samples for bacterial identification and produce more accurate diagnoses for patients.

Bio-Rad SARS-CoV-2 variant neutralization antibody assays

February 2022—Bio-Rad Laboratories launched the Bio-Plex Pro Human SARS-CoV-2 Variant Neutralization Antibody Assays, for research use only. The assays allow scientists to measure neutralizing antibodies against wild-type and significant variants of the SARS-CoV-2 virus. The Bio-Plex Pro Human SARS-CoV-2 Variant Neutralization Antibody 11-Plex Panel is a ready-to-use 96-well kit containing premixed magnetic capture beads, a detection ACE2 receptor, a standard and positive control, and buffers that measure levels of neutralizing antibodies and percentage inhibition of the ACE2 receptor binding the viral antigens coupled on the beads.

Biodesix launches GeneStrat NGS, IQLung testing strategy

February 2022—Biodesix announced the launch of its GeneStrat NGS genomic test, a blood-based tumor profiling test. The 52-gene panel includes guideline-recommended mutations to help physicians treating advanced-stage lung cancer patients identify targeted therapy mutations, such as EGFR, ALK, KRAS, MET, NTRK, ERBB2, and others.

Qiagen, Denovo to develop CDx for treatment of DLBCL

February 2022—Qiagen and Denovo Biopharma will collaborate to develop a blood-based companion diagnostic test to identify patients expressing Denovo Genomic Marker 1 (DGM1) who are likely to respond to Denovo’s investigational cancer drug DB102 for treatment of diffuse large B-cell lymphoma. DB102 (enzastaurin) is an investigational small molecule inhibitor of PKC-beta, which, if present, has been linked to DLBCL cases.

Clinical reference materials for cholesterol, electrolytes

February 2022—Verichem Laboratories offers an array of liquid-stable, ready-to-use multilevel reference materials for total cholesterol, high-density lipoprotein, and low-density lipoprotein testing. The Matrix Plus Total Cholesterol Reference Kit, the Matrix Plus Total Cholesterol Reference Level F, and the HDL Cholesterol Verifier Kit are intended for calibration verification and are compatible with a variety of wet chemistry clinical analyzers.

Roche COVID-19 at-home test granted EUA

February 2022—Roche announced that the FDA has granted emergency use authorization for its COVID-19 At-Home Test. The test uses an anterior nasal swab sample that can be self-collected and self-tested by people ages 14 years and older and by an adult for children ages two to 13 years old. Results are available in as few as 20 minutes for SARS-CoV-2 and all known variants of concern, including omicron.

EliTechGroup PCR kit differentiates SARS-CoV-2 omicron variant

February 2022—EliTechGroup MDx announced its research use only SARS-CoV-2 Extended test kit reliably differentiates the SARS-CoV-2 omicron (B.1.1.529) variant from other variants of concern. The in silico analysis was confirmed by testing patient samples positive for different SARS-CoV-2 variants including omicron. The SARS-CoV-2 Extended RUO reagents differentiate the alpha, beta, gamma, delta, and omicron variants in a single multiplex PCR and test for the presence of specific mutations in the regions of the S gene corresponding to positions 452, 484, and 501 of the spike protein. The combination of the melting curve analysis and the optical channel information allows for unambiguous differentiation of the five SARS-CoV-2 variants. The results can be interpreted and released when the reagents are used on the sample-to-result Elite InGenius system.

From the President’s Desk

The time for courage
February 2022—We pathologists tend to share traits common among physicians: We are often type A overachievers, driven by perfectionism, our own unrealistic expectations, and a deep fear of failure. Normally, these characteristics help us to achieve our goals, in life and in caring for patients. But these are not normal times. In the COVID-19 pandemic, it is almost impossible to feel like we’re doing a good job. Like so many of you, I am working significantly long­er hours than usual. At the end of each day I am often left with a sense of despondency that there’s not enough time to get everything done, or to do it all as well as I would like.To get through this crisis, we have to let go of our perfectionism and embrace doing what we can. We need to accept that if we’re doing what we can, it’s enough. Even if our individual efforts seem inadequate in dealing with this pandemic nightmare, the collective effort is adequate. Each day in my hospital I feel like I’m taking a bath in COVID-19. But I go home, rest up, and do it again the next day.

Clinical pathology selected abstracts

• Association of preanalytical error with use of outdoor courier lockboxes in summer
• Enhancing diversity, equity, and inclusion in pathology training programs

MARKETPLACE

TRENDING